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STUDY QUESTION: Does administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) in the ﬁrst trimester
improve pregnancy outcomes, among women with a history of unexplained recurrent pregnancy loss?
SUMMARY ANSWER: rhG-CSF administered in the ﬁrst trimester of pregnancy did not improve outcomes among women with a history
of unexplained recurrent pregnancy loss.
WHAT IS KNOWN ALREADY: The only previous randomized controlled study of granulocyte colony stimulating factor in recurrent mis-
carriage in 68 women with unexplained primary recurrent miscarriage found a statistically signiﬁcant reduction in miscarriage and improve-
ment in live birth rates. A further four observational studies where G-CSF was used in a recurrent miscarriage population were identiﬁed in
the literature, two of which conﬁrmed statistically signiﬁcant increase in clinical pregnancy and live birth rates.
STUDY DESIGN, SIZE, DURATION: A randomized, double-blind, placebo controlled clinical trial involving 150 women with a history of
unexplained recurrent pregnancy loss was conducted at 21 sites with established recurrent miscarriage clinics in the United Kingdom between
23 June 2014 and 05 June 2016. The study was coordinated by University of Birmingham, UK.
PARTICIPANTS/MATERIALS, SETTING, METHODS: One hundred and ﬁfty women with a history of unexplained recurrent preg-
nancy loss: 76 were randomized to rhG-CSF and 74 to placebo. Daily subcutaneous injections of recombinant human granulocyte – colony
stimulating factor 130 μg or identical appearing placebo from as early as three to ﬁve weeks of gestation for a maximum of 9 weeks. The trial
used central randomization with allocation concealment. The primary outcome was clinical pregnancy at 20 weeks of gestation, as demon-
strated by an ultrasound scan. Secondary outcomes included miscarriages, livebirth, adverse events, stillbirth, neonatal birth weight, changes
in clinical laboratory variables following study drug exposure, major congenital anomalies, preterm births and incidence of anti-drug antibody
formation. Analysis was by intention to treat.
MAIN RESULTS AND THE ROLE OF CHANCE: A total of 340 participants were screened for eligibility of which 150 women were
randomized. 76 women (median age, 32[IQR, 29–34] years; mean BMI, 26.3[SD, 4.2]) and 74 women (median age, 31[IQR, 26–33] years;
mean BMI, 25.8[SD, 4.2]) were randomized to placebo. All women were followed-up to primary outcome, and beyond to live birth. The clin-
ical pregnancy rate at 20 weeks, as well as the live birth rate, was 59.2% (45/76) in the rhG-CSF group, and 64.9% (48/74) in the placebo
group, giving a relative risk of 0.9 (95% CI: 0.7–1.2; P = 0.48). There was no evidence of a signiﬁcant difference between the groups for any of
the secondary outcomes. Adverse events (AEs) occurred in 52 (68.4%) participants in rhG-CSF group and 43 (58.1%) participants in the
© The Authors 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
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placebo group. Neonatal congenital anomalies were observed in 1/46 (2.1%) of babies in the rhG-CSF group versus 1/49 (2.0%) in the pla-
cebo group (RR of 0.9; 95% CI: 0.1–13.4; P = 0.93).
LIMITATIONS, REASONS FOR CAUTION: This trial was conducted in women diagnosed with unexplained recurrent pregnancy loss
and therefore no screening tests (commercially available) were performed for immune dysfunction related pregnancy failure/s.
WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this is the ﬁrst multicentre study and largest randomized clinical trial
to investigate the efﬁcacy and safety of granulocyte human colony stimulating factor in women with recurrent miscarriages. Unlike the only
available single center RCT, our trial showed no signiﬁcant increase in clinical pregnancy or live births with the use of rhG-CSF in the ﬁrst tri-
mester of pregnancy.
STUDY FUNDING/COMPETING INTEREST(S): This study was sponsored and supported by Nora Therapeutics, Inc., 530 Lytton
Avenue, 2nd Floor, Palo Alto, CA 94301, USA. Darryl Carter was the co-founder and VP of research, Nora Therapeutics, Inc. and held
shares in the company. He holds a patent for the use of recombinant human granulocyte colony stimulating factor to reduce unexplained
recurrent pregnancy loss. Mark Joing, Paul Kwon and Jeff Tong were or are employees of Nora Therapeutics, Inc. No other potential conﬂict
of interest relevant to this article was reported.
TRIAL REGISTRATION NUMBER: EUDRACT No: 2014-000084-40; ClinicalTrials.gov Identiﬁer: NCT02156063
TRIAL REGISTRATION DATE: 31 Mar 2014
DATE OF FIRST PATIENT’S ENROLMENT: 23 Jun 2014
Key words: recombinant human granulocyte colony stimulating factor / cytokine / neutropenia / recurrent pregnancy loss / semi-
allogenic fetus / immune mediated miscarriages / unexplained recurrent miscarriages
Introduction
Recurrent pregnancy losses (RPL) deﬁned as the loss of three or more
pregnancies, affects ~1–3% of couples attempting to have a child (Ford
and Schust, 2009). Investigations do not provide a cause for recurrent
pregnancy losses in approximately half of those investigated, and such
couples are said to have unexplained recurrent pregnancy losses (Jeve
and Davies, 2014). Whilst a range of treatments are currently offered
to couples with unexplained recurrent pregnancy losses (uRPL), no
effective treatment has yet been identiﬁed (ESHRE Recurrent
Pregnancy Loss Guidelines, 2017).
Immune mediated mechanisms are thought to contribute to recur-
rent pregnancy losses. In particular, a failure of the maternal immune
system to adapt to accommodate the semi-allogenic fetus may be
important. Despite a lack of good evidence of their efﬁcacy, a range of
immunomodulatory treatments including, paternal lymphocyte infu-
sion therapy (Mowbray et al., 1985, Cavalcante et al., 2014), corticos-
teroids, intravenous immunoglobulin therapy (Nyborg et al., 2014),
intravenous intralipid infusion (Meng et al., 2016) and anti–TNFα
monoclonal antibody therapy (Clark, 2009) to modulate the maternal
immune response are offered to women with recurrent pregnancy
losses.
Granulocyte colony stimulating factor (G-CSF) is a cytokine conven-
tionally viewed as important in stimulating the proliferation and differ-
entiation of neutrophils (Thomas et al., 2002). It is widely used in
treatments associated with severe chronic neutropenia and chemo-
therapy induced neutropenia for mobilization of neutrophils (Carton
et al., 2013). In addition, G-CSF is postulated to have immunomodula-
tory properties by inducing peripheral regulatory T-cells and myeloid
derived suppressor cells, which have an important function curbing the
immune response to infection, inﬂammation, and autoimmunity
(Williams, 2012). Furthermore, studies in both humans and animals
have showed that administration of G-CSF improves endometrial
thickness (Gleicher et al. 2011), ovarian follicular function and oocyte
quality (Salmassi et al., 2004), which may enhance embryo implant-
ation (Ledee et al., 2008).
A Phase 1 randomized double blind, placebo-controlled dose escal-
ation (65 mcg, 130 mcg and 260 mcg) study of recombinant human
(rh) G-CSF in 48 healthy female volunteers suggested changes in per-
ipheral blood subsets including a temporary induction of toleragenic
cell subsets and decreased percentages of pro-inﬂammatory and cyto-
toxic cell subsets, without evidence of global immune changes or sup-
pression. These speciﬁc changes were observed only in the multidose
groups and not in single dose or placebo groups (unpublished data;
available on request through the corresponding author).
Furthermore, a single center, randomized controlled trial of 68
women diagnosed with recurrent pregnancy losses, suggested that
rhG-CSF may be an effective treatment (Scarpellini and Sbracia, 2009).
Although the clinical evidence is limited (ESHRE Recurrent Pregnancy
Loss Guidelines, 2017), the use of G-CSF to treat recurrent miscar-
riage and implantation failure appears to be increasing. Therefore,
there was an urgent need to determine the efﬁcacy and safety of this
treatment in a multicentre trial.
We conducted a multicentre, randomized, double-blind, placebo-
controlled trial to evaluate the efﬁcacy and safety of recombinant
human granulocyte colony stimulating factor (rhG-CSF) in women with
a history of unexplained recurrent pregnancy loss to provide a deﬁni-
tive answer on whether rhG-CSF administration improved pregnancy
outcomes.
Materials andMethods
Study design
RESPONSE study was a multicentre, double blind; placebo controlled ran-
domized clinical trial conducted to determine the effect of recombinant
2 Eapen et al.
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human granulocyte – colony stimulating factor in women with a history of
unexplained recurrent pregnancy loss. All the eligible participants gave
their written informed consent. The participants in the RESPONSE trial
were recruited from 21 hospitals with established recurrent pregnancy
loss clinics located across the United Kingdom. Study enrollment occurred
between June 2014 and June 2016. The study was approved by NRES
Committee North West – Greater Manchester Central (REC Ref.No: 14/
NW/0130) and the individual research and development departments at
respective hospital sites.
Participants
Women were eligible for enrollment in the study: (1) if they were aged
18–37 years with a BMI of 19–35 (at the time of consent), and (2) with
regular ovulatory menstrual cycles and those who were actively trying to
conceive naturally after being diagnosed with a history of unexplained
recurrent pregnancy loss (three or more consecutive or non-consecutive
ﬁrst trimester losses of which at least two were conﬁrmed by ultrasound
or by histology). Age criterion was applied because the likelihood of mis-
carriages due to chromosomal aberrations is higher in older women, with
such miscarriages unlikely to be prevented by immune-modulation.
Participants were excluded if any of the following criteria were applicable
(a) greater than 5 completed weeks of gestation (i.e. greater than 3 com-
pleted weeks since ovulation as indicated by ovulation monitoring) when
presenting for randomization, (b) known karyotype abnormalities in either
the participant or her current male partner, (c) congenital malformations
and uncorrected major and minor uncorrected intrauterine abnormalities
(as assessed by ultrasound, hysterosonography, hysterosalpingography, or
hysteroscopy within 3 years prior to screening), (d) vaginal bleeding of
unknown cause, (e) diagnosis of infertility, (f) current or past diagnosis of the
following: systemic autoimmune disease (e.g. systemic lupus erythematosus,
Hashimoto’s thyroiditis, Graves’ disease, rheumatoid arthritis), antiphospho-
lipid syndrome, or other thrombophilic disorder, (g) presence of anti-
thyroid antibodies, lupus anticoagulant, anti-cardiolipin antibodies, or anti-β2
GP1 antibodies, (h) hyperprolactinemia, (i) any uncontrolled clinically signiﬁ-
cant medical condition (e.g. asthma, type II diabetes, infection), (j) the fol-
lowing laboratory abnormalities at initial screening or within 3 months prior
to randomization: thrombocytopenia or thrombocytosis (platelet count
<75,000/μL or > 500,000/μL), neutropenia or neutrophilia (absolute neu-
trophil count <1500/μL or > 10,000/μL), leucopenia or leucocytosis (white
blood cell count <3000/μL or >15,000/μL), and creatinine, hepatic transa-
minases, lactate dehydrogenase (LDH), alkaline phosphatase, or uric acid
≥1.5× upper limit of normal (ULN), (k) use of lithium within 1 month prior
to screening, (l) known hypersensitivity to any rhG-CSF drug product, any of
its components, or any E. coli-derived proteins, (m) history of any of the fol-
lowing conditions: human immunodeﬁciency virus (HIV) infection, (n) malig-
nancy within the past 5 years other than treated basal cell carcinoma or
squamous cell carcinoma of the skin, (o) splenomegaly or splenic rupture,
(p) adult respiratory distress syndrome (ARDS), acute lung injury (ALI), or
pulmonary edema, (q) sickle cell anemia, (r) acute myocardial infarction,
stroke, or revascularization (coronary or cerebral), (s) previous rhG-CSF
therapy for any indication, or (t) in the investigator’s opinion, any contraindi-
cation to use of the investigational drug.
Randomization, masking and procedures
Participants in RESPONSE trial were randomized to receive rhG-CSF
130 mcg or placebo in a 1:1 ratio. Stratiﬁed permuted block randomization
was used with number of prior miscarriages (3, >3), and age (<35, 35–37
years) as the stratiﬁcation factors. An interactive central web response sys-
tem (IWRS) was used for randomization.
Eligible participants were identiﬁed from recurrent pregnancy loss clinics
and underwent comprehensive screening tests for eligibility evaluation.
Once eligibility was established, the participant began ovulation monitoring
and attempts at spontaneous conception. The participant performed daily
urine pregnancy tests from 6 days after ovulation. After reporting a posi-
tive home urine pregnancy test, the participant scheduled a visit to the
study site for a repeat urine pregnancy test, randomization into the study
and initiation of study drug treatment. The study site visit took place within
4 days of the positive home urine pregnancy test. Once randomized, the
participant self-administered rhG-CSF or placebo as a subcutaneous injec-
tion for a maximum of 9 weeks (up to 12th week of gestation) or until
pregnancy failure.
Recombinant human granulocyte colony stimulating factor (rhG-CSF)
and placebo were supplied to the investigative site in single-use 1 mL pre-
ﬁlled syringes. Each preﬁlled syringe contained 0.5 mL of rhG-CSF 260 μg/
mL for the 130 μg dose, or identical appearing placebo. Participants, doc-
tors and trial nurses remained unaware of study assignments. The ﬁrst
dose of study drug was administered at the investigative site. All subse-
quent doses were administered by the participant once daily at approxi-
mately the same time each day (within 20–28 h after the previous dose).
All study data except central laboratory and immunogenicity data were
recorded in an electronic case report form (eCRF). Research personnel
allocated for the trial at individual sites were responsible for entering these
data.
Immunogenicity and safety analysis
All participants receiving study drug had serum samples collected prior to
study drug administration, and at 6, 12 and 16 weeks of gestation or 4
week post drug follow up (for participants diagnosed with pregnancy loss)
for the presence of anti-drug antibodies (ADAs). Safety was monitored
through the assessment of adverse events, vital signs, physical examina-
tions and clinical laboratory variables throughout the treatment period and
4-week post drug follow-up period by a designated medical monitor. In
order to minimize unnecessary exposure to study drug, any randomized
participant who was no longer pregnant discontinued study drug prior to
the completion of the treatment period and was followed for a minimum
of 4 weeks after last dose of study drug.
An external and independent Data Monitoring Committee (DMC) facili-
tated close monitoring of safety data, including any deaths, serious adverse
events, anti-drug antibody formation and adverse events of special interest
including splenic rupture, anaphylaxis, acute respiratory distress syndrome
(ARDS) or acute lung injury (ALI) and major cardiovascular event.
Study blinding
This study was randomized, double-blinded and placebo-controlled to
minimize potential bias in treatment assignment, subject monitoring, and
endpoint evaluations. All participants, subjects, investigative center study
staff, and investigative center monitors were blinded to treatment assign-
ment. In addition, the laboratory results for white blood cells (WBC) and
WBC subset counts, alkaline phosphatase, uric acid, lactate dehydrogen-
ase (LDH) and anti-drug antibody (ADA) was blinded, as it had the poten-
tial for unblinding the intervention.
Outcomes
The primary outcome of ongoing clinical pregnancy was assessed via ultra-
sound examination at 20 weeks of gestation. All participants were moni-
tored for adverse events. All participants who received at least one dose
of study drug were followed for safety for a minimum of 4 weeks following
the last dose of study drug.
The secondary outcome measures were: (a) live birth, (b) ongoing clin-
ical pregnancy at weeks 6 and 12 of gestation, (c) spontaneous pregnancy
loss, (d) elective abortion, (e) stillbirth, (f) neonatal birth weight,
3rhG-CSF and recurrent miscarriage
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(g) maternal adverse events and serious adverse events during the treat-
ment period and within 4 weeks of the last dose of study drug, (h) changes
in clinical laboratory variables following study drug exposure, (i) major con-
genital anomalies, (j) preterm births and (k) incidence of anti-drug antibody
(ADA) formation.
For participants who maintained pregnancy through 20 weeks of gesta-
tion, phone visits were conducted every 8 weeks during pregnancy to
assess pregnancy status/outcomes and prescription medication use.
Within one month of delivery, additional information was obtained, includ-
ing pregnancy outcome, gestational age at delivery, mode of delivery, birth
weight and Apgar scores.
Sample size calculations
The target sample size was a total of 150 participants. Participants were
randomized in a 1:1 ratio to the two treatment arms. This sample size had
been selected to achieve >90% power to detect a difference in ongoing
clinical pregnancy rates of 60% for the placebo group and 80% in the active
treatment group. Efﬁcacy analysis was based on an intent-to-treat prin-
ciple. The difference in the primary efﬁcacy outcome measure (ongoing
clinical pregnancy rate at week 20 of gestation) between rhG-CSF and pla-
cebo was tested using a Cochran Mantel Haenszel (CMH) test.
Statistical analysis
The statistician who conducted the analysis was blinded to group alloca-
tion. Efﬁcacy analysis was based on an intention to treat principle. The rela-
tive risks (RRs) with 95% CIs were calculated for the primary and
secondary outcomes. Subgroup analysis was performed using the RR for
the stratiﬁcation factors. Missing data were imputed only for those with a
clinical pregnancy and livebirth. This implied that summary measures were
limited to participants who remained pregnant at that time point. The stat-
istical analysis plan (SAP) is available in Supplementary material.
Results
Between 23 June 2014 and 05 June 2016, a total of 340 women were
screened for inclusion criteria at 21 different recruiting centers in the
United Kingdom. One hundred and ninety women did not meet the
inclusion criteria. One hundred and ﬁfty women who conceived natur-
ally and remained willing to participate in the trial were randomized to
receive either rhG-CSF (76 women) or placebo (74 women) (Fig. 1).
Overall, 140/150 women (93.3%) completed the study and 10/150
women (6.7%) discontinued the study prematurely for reasons
Screened for eligibility (n = 340) 
Ineligible (n = 190) 
 Analysed (n = 76) 
     77 Fetuses 
Completed study (n = 72) 
     Includes  
     27 early pregnancy failures 
       1 Non-compliant 
Randomised to rhG-CSF (n = 76)     
Discontinued study (n = 4) 
         2 Lost to follow up 
Completed study (n = 68) 
     Includes 
     23 early pregnancy failures 
1 Non-compliant 
Randomised to Placebo (n = 74) 
Discontinued study (n = 6) 
5 Lost to follow up 
Analysed (n = 74)  
     76 Fetuses 
Randomised (n = 150) 
Figure 1 Participant ﬂow diagram.
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including loss to follow up, withdrawal of consent, and other reasons
(for e.g. use of any excluded therapy).
All participants were followed to primary outcome, and beyond to
live birth. The baseline characteristics of the study population were
similar across the study groups (Table I). The median age at the time
of recruitment was 30.6 years (IQR 29–34 years) and 37 participants
(24.7%) had experienced more than three previous miscarriages. The
mean BMI at the time of randomization was 26.06 kg/m2. Ethnicity
data was available for all 150 randomized women, and of these, 134
(89%) were white, 9 (6%) were Asian, 2 (1%) were black and 5 (3%)
were from other ethnic groups. Most of the women were non-
smokers (123/150, 82%). Study records of concurrent medications
showed that 3 (2%) participants were taking metformin at the time of
participation, and 23 (15.3%) were taking low dose aspirin.
Treatment compliance
Subject compliance with study drug dosing was accessed via a site
review of the returned syringes and the compliance record maintained
by the participant. From these results, summaries of treatment
.............................................................................................................................................................................................
Table I Baseline characteristics of the participants (intention to treat analysis)a.
rhG-CSF Placebo
Characteristics (N = 76) (N = 74)
Maternal age – yrb
Median 32 31
Interquartile range 29–34 26–33
Maternal BMI 26.3 ± 4.2 25.8 ± 4.2
Maternal BMI >30 – no. (%) 17 (22.4) 13 (17.6)
Maternal race – no. (%)c
White 71 (93.4) 63 (85.1)
Black 0 2 (2.7%)
Asian 4 (5.3) 5 (6.8)
Other, including mixed race 1 (1.3) 1 (5.4)
Maternal smoking – no (%)
Nonsmoker 62 (81.6) 61 (82.4)
<10 cigarettes/day 10 (13.2) 7 (9.5)
10 to 19 cigarettes/day 3 (3.9) 6 (8.1)
≥20 cigarettes/day 1 (1.3) 0
Alcohol use – no. (%)d
None 36 (47.4) 35 (47.3)
≤3 units/day 27 (35.5) 26 (35.1)
>3 to ≥20 units/day 13 (17.1) 13 (17.6)
>20 units/day 0 0
Parity
Previous live birth – no. (%) 38 (50.0) 37 (50.0)
≥4 previous miscarriages – no. (%) 40 (52.6) 40 (54.1)
Previous pregnancy losses – no.
Median 4.0 4.0
Interquartile range 3–5 3–5
Clinical risk factors – no. (%)
Polycystic ovaries 2 (2.6) 6 (8.1)
Fibroids 5 (6.6) 3 (4.1)
Large-loop excision of the cervical transformation zone 2 (2.6) 8 (10.8)
Concurrent medications – no. (%)
Metformin 1 (1.3) 2 (2.7)
Aspirin 13 (17.1) 10 (13.5)
aPlus – minus values are means ± SD. The baseline data (age, body mass index [BMI; the weight in kilograms divided by the square of the height in meters], maternal race, smoking sta-
tus and parity) of the participants were similar in the two study groups.
bListed is the maternal age at the time of randomization.
cRace was self-reported.
dOne unit is 10 g of pure alcohol.
5rhG-CSF and recurrent miscarriage
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compliance and exposure were produced. In the overall population,
the mean (SD) compliance rate was 98.7% (3.99).
Outcomes of the participants
The clinical pregnancy rate at 20 weeks of gestation was 59% (45/76)
in the rhG-CSF group, compared with 65% (48/74) in the placebo
group, giving a RR of 0.9 (95% CI: 0.7–1.2; P = 0.48) (Table II). There
were no pregnancy losses in the time period from primary outcome to
live birth; therefore the live birth rate was 59.2% (45/76) in the rhG-
CSF group, and 64.9% (48/74) in the placebo group, giving a relative
risk of 0.9 (95% CI: 0.7–1.2; P = 0.48). During the study, clinical preg-
nancies were conﬁrmed by ultrasound scan at 6 weeks of gestation in
136 (90.7%) of the 150 randomized participants [67/76, 88.2% in the
rhG-CSF group vs 69/74, 93.2% in the placebo group, RR of 0.9 (95%
CI: 0.9–1.0; P = 0.28)]. Ongoing pregnancies were conﬁrmed at ~12
weeks in 96 (64.0%) of the women [45/76, 59.2% in the rhG-CSF
group versus 51/74, 68.9% in the placebo group, RR of 0.9 (95% CI:
0.7–1.1; P = 0.224)].
Miscarriage rates were not signiﬁcantly different between the study
groups (rhG-CSF 28/76, 36.8% versus placebo 25/74, 33.8%, RR of
1.1 (95% CI: 0.7–1.7, P = 0.70)). Amongst the 28 pregnancies that
ended in miscarriage for participants receiving rhG-CSF, the median
gestation was 6 weeks (IQR 6–7 weeks). Amongst the 25 pregnancies
that ended in miscarriage for participants receiving placebo, the
median gestation was 6.5 weeks (IQR 6–9 weeks). The distributions
of gestational age at live birth delivery for the rhG-CSF and placebo
groups are given in Fig. 2. All infants were discharged home alive from
the hospital.
Adverse events (AEs) occurred in 52 (68.4%) participants in rhG-
CSF group and 43 (58.1%) participants in the placebo group
(Supplementary Table SI). Neonatal congenital anomalies were
observed in 1/46 (2.1%) of babies in the rhG-CSF group versus 1/49
(2.0%) in the placebo group (RR of 0.9; 95% CI: 0.1–13.4; P = 0.93).
Findings of subgroup analyses are given in Supplementary Table SII;
no signiﬁcant subgroup effects were identiﬁed. Exploratory analyses
for a number of key obstetric outcomes did not ﬁnd any signiﬁcant dif-
ferences between the rhG-CSF and placebo arms.
Discussion
This randomized clinical trial investigating the effect of recombinant
human granulocyte colony stimulating factor in the ﬁrst trimester of
pregnancy in women, diagnosed with unexplained recurrent pregnancy
.............................................................................................................................................................................................
Table II Primary outcome and secondary outcomes of participants in this trial.
rhG-CSF Placebo Relative risk P value
no./total no. (%) (95% CI)
Primary outcome
Live birth after 20 weeks of gestation 45/76 (59.2) 48/74 (64.9) 0.9 (0.7, 1.2) 0.48
Secondary outcomes
Pregnancy outcomes
Clinical pregnancy at 6 weeks 67/76 (88.2) 69/74 (93.2) 0.9 (0.9, 1.0) 0.28
Ongoing pregnancy at 8 weeks 51/76 (67.1) 59/74 (79.7) 0.8 (0.7, 1.0) 0.09
Ongoing pregnancy at 12 weeks 45/76 (59.2) 51/74 (68.9) 0.9 (0.7, 1.1) 0.22
Live birth after 24 weeks of gestation 45/76 (59.2) 48/74 (64.9) 0.9 (0.7, 1.2) 0.48
Live birth after 34 weeks of gestation 45/76 (59.2) 42/74 (56.8) 1.0 (0.8, 1.4) 0.76
Ectopic pregnancy 1/76 (1.3) 0/74 (0.0) NA NA
Miscarriagea 28/76 (36.8) 25/74 (33.8) 1.1 (0.7, 1.7) 0.70
Stillbirth 0/76 (0.0) 0/76 (0.0) NA NA
Preterm birth (before 37 weeks 0 days of gestation) 5/45 (11.1) 8/48 (16.7) 0.7 (0.3, 2.0) 0.54
Infant birth weight (g)
Median 3420.0 3300.0 NA NA
Range 3005–3920 2690–3610 NA NA
Neonatal outcomesb
Infants discharged alive from hospital 46/46 (100.0) 49/49 (100.0) NA NA
Any congenital anomaly 1/46 (2.2) 1/49 (2.0) 0.9 (0.1, 13.4) 0.93
Adverse eventsc n/N (%) n/N(%)
Maternal adverse events 52/76 (68.4) 43/74 (58.1) 1.2 (0.9, 1.5) 0.20
Serious adverse events 4/76 (5.2) 2/74 (2.7) 1.9 (0.3, 10.3) 0.43
Incidence of anti-drug antibody formation 0/76 (0.0) NA NA NA
aMiscarriage was deﬁned as spontaneous loss of a pregnancy less than 24 weeks of gestation; the median gestational age at miscarriage was 6.0 weeks (interquartile range, 6–7) in the
rhG-CSF and 6.5 weeks (interquartile range, 6–9) in the placebo group. There were three pregnancies of unknown location in the rhG-CSF group.
bThe end point is listed per neonate.
cPlease see Supplementary Table SI for details.
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loss, found no improvement in clinical pregnancies at 20 weeks, or live
births, compared to placebo.
Comparison with previous studies
The ﬁndings from this large multicentre, randomized, placebo-
controlled trial do not support the ﬁndings of the only previous rando-
mized control study evaluating recombinant G-CSF in recurrent preg-
nancy loss (Scarpellini and Sbracia, 2009). In this previous, smaller,
single center study by Scarpellini and Sbracia, 68 women with a previ-
ous history of unexplained recurrent miscarriage were randomized to
G-CSF or placebo. Women in the intervention group were started on
a dose of 1 mcg/kg/day starting on sixth day after ovulation. The live
birth rates in the rhG-CSF group was 82.8% versus 48.5% in the pla-
cebo group (P = 0.0061, OR = 5.1; 95% conﬁdence interval 1.5–18.4),
suggesting a statistically signiﬁcant improvement in outcomes.
There are also two retrospective cohort studies in women with
recurrent miscarriage which suggested improved outcomes with
administration of G-CSF (Santjohanser et al., 2013, Würfel, 2013).
Observational data from two separate population registry was also
identiﬁed. Boxer et al., identiﬁed 224 pregnancy events in women diag-
nosed with chronic neutropenia and identiﬁed a decrease in abortion
rates with no adverse side effects (Boxer et al., 2010). However,
Zeidler et al., used data from severe chronic neutropenia international
registry (SCNIR) and observed no improvement in pregnancy out-
comes after administration of G-CSF (Zeidler et al., 2014). All the
above studies used a varying dose and duration of G-CSF and were of
poor quality (ESHRE Recurrent Pregnancy Loss Guidelines, 2017).
rhG-CSF is also widely used in assisted conception treatment. A
previous review of G-CSF in reproductive medicine studies also sug-
gested therapeutic beneﬁt based on body weight dependent target
dose or use of G-CSF as an intrauterine infusion (Cavalcante et al.,
2015). This review included 1 RCT, 5 cohort studies and 1 case report
in a varied range of patients. The included studies were of poor quality
and the researchers called for larger well-designed studies. A more
recent randomized open label clinical trial of G-CSF (using a single
dose of 300 μg as an intrauterine infusion on day of oocyte recovery)
in 100 infertile women undergoing in-vitro fertilization treatment did
not show a beneﬁt of G-CSF in improving pregnancy outcomes
(Eftekhar et al., 2016).
Strength and limitations of this study
The strengths of our study include the multicentre study design involv-
ing 21 hospitals spread across the United Kingdom. After standard
screening tests, as practiced in the United Kingdom, 150 women with
unexplained recurrent pregnancy losses from different ethnic back-
ground were randomized. Thus, our study represents the largest
placebo-controlled randomized control study of rhG-CSF in women
with unexplained recurrent pregnancy losses. Participant compliance
rate was high and all participants were followed up until completion of
study endpoints, as appropriate. Unlike other studies where a varying
dose of G-CSF was utilized, we initiated optimal dosage of rhG-CSF
treatment as soon as the pregnancy was conﬁrmed, which started as
early as 7 days after ovulation. A Phase 1, randomized, double-blind,
placebo-controlled, dose-escalation study was conducted prior to this
study for dosage determination. This study consisted of six single- and
multiple-dose cohorts with eight participants in each dose cohort, ran-
domized in a 3:1 ratio to receive either rhG-CSF or placebo. Transient
neutrophilia and increases in white blood cell (WBC) counts were
observed following both single and multiple doses. Changes in periph-
eral blood cell subsets were observed consistent with supporting a
state of maternal–fetal immune tolerance. These changes include the
temporary induction of toleragenic cell subsets including an increase in
toleragenic myeloid derived suppressor cells (MDSC) and a decrease
in cytotoxic natural killer (NK) cells, without evidence of global
immune changes or suppression. These changes were observed only
in the multidose rhG-CSF treatment groups, and not in any placebo
group. The weakness of our study was that women were not screened
prior to inclusion to demonstrate immune dysfunction as the reason
for their pregnancy losses. This is because there is no accepted test(s)
for immune dysfunction in reproductive immunology.
Figure 2 Distribution of gestational age according to study group assignment. Only pregnancies which continued beyond 24 weeks are
shown.
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There was no increased risk of congenital anomalies among offspring
of women treated with rhG-CSF, although the study was not powered
for such rare outcomes.
Conclusion
Among women with a history of unexplained recurrent pregnancy
loss, administration of rhG-CSF in the ﬁrst trimester of pregnancy,
compared with placebo, did not improve the clinical pregnancy rates
at 20 weeks or live birth rates.
Supplementary data
Supplementary data are available at Human Reproduction online.
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